Scarica l'app Stockscreener
58.14
9.35%
-6.00
Precedente Chiudi:
$64.14
Aprire:
$63.74
Volume 24 ore:
2.37M
Relative Volume:
2.90
Capitalizzazione di mercato:
$2.54B
Reddito:
$535.08M
Utile/perdita netta:
$-48.27M
Rapporto P/E:
-51.29
EPS:
-1.1335
Flusso di cassa netto:
$-31.54M
1 W Prestazione:
-11.16%
1M Prestazione:
-5.11%
6M Prestazione:
-24.37%
1 anno Prestazione:
+41.25%
Intervallo 1D:
$57.51
$63.84
Intervallo di 1 settimana:
$57.51
$72.50
Portata 52W:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Nome
Tarsus Pharmaceuticals Inc
Settore
Industria
Telefono
(949) 409-9820
Indirizzo
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
58.14 | 2.54B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-27 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-20 | Iniziato | Goldman | Neutral |
| 2023-07-18 | Iniziato | William Blair | Outperform |
| 2023-05-18 | Iniziato | Guggenheim | Buy |
| 2022-08-01 | Iniziato | Barclays | Overweight |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-23 | Iniziato | Oppenheimer | Outperform |
| 2020-11-10 | Iniziato | BofA Securities | Buy |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-11-10 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline - Yahoo Finance
How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing - Stock Traders Daily
Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101 - VisionMonday.com
All you need to know about Tarsus Pharmaceuticals (TARS) rating upgrade to buy - MSN
Tarsus Pharmaceuticals Acquires iRenix for $75M - Orange County Business Journal
TARS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $88 - GuruFocus
Tarsus Pharmaceuticals (TARS) Q3 2024 earnings summary - Quartr
Tarsus Pharmaceuticals, Inc. (TARS) iRenix Medical, Inc.,M&A CallSlideshow (NASDAQ:TARS) 2026-07-09 - Seeking Alpha
Tarsus Pharmaceuticals (TARS) M&A announcement Summary - Quartr
Tarsus Pharmaceuticals (TARS) Acquires iRenix Medical for $75M - GuruFocus
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront - Investing.com
Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 - MSN
TARS Acquires iRenix Medical for $75M in a Strategic Move - GuruFocus
Tarsus Pharmaceuticals Acquires iRenix With $37.5M Cash, Stock; Milestones Up to $490M - TradingView
Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset - Stock Titan
Press Release: Tarsus Advances Eye Care Leadership Strategy With Acquisition of IRenix Medical and Late-Stage Asset IRX-101 - Moomoo
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy - Yahoo! Finance Canada
Tarsus Pharmaceuticals (TARS) Holds Steady Near Midpoint: Support and Resistance in FocusGap and Reverse - dars.gov.et
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus Pharmaceuticals (TARS) moves 7.5% higher: Will this strength last? - MSN
Enterprise value to revenue forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Price to earnings forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Price to sales forward of Tarsus Pharmaceuticals, Inc. – NASDAQ:TARS - TradingView
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last? - Yahoo Finance
Did Copay Allegations and New Director Equity Awards Just Shift Tarsus Pharmaceuticals' (TARS) Investment Narrative? - Sahm
TARSTarsus Pharmaceuticals Inc Short Interest - Finviz
Tarsus Pharmaceuticals stock jumps as investors revisit XDEMVY growth outlook - Quiver Quantitative
Tarsus Pharmaceuticals falls amid Culper Research short call - MSN
Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall - Moomoo
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Yahoo Finance
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme - Benzinga
TARS: Concerns Raised Over Tarsus Pharmaceuticals' Business Prac - GuruFocus
Culper Research Says We Are Short Tarsus Pharmaceuticals - TradingView
Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Tarsus (TARS) director awarded RSUs and options for 6,254 shares - Stock Titan
Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants - Stock Titan
Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options - Stock Titan
Equity awards grant Tarsus (TARS) director RSUs and stock options - Stock Titan
Tarsus (TARS) director receives new RSU and stock option awards - Stock Titan
Tarsus (TARS) director Wendy Yarno receives RSU and option grants as board pay - Stock Titan
Tarsus (TARS) director William J. Link granted options and RSUs - Stock Titan
Tarsus (NASDAQ: TARS) holders back board, pay and auditor - Stock Titan
(TARS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Tarsus Pharmaceuticals Inc (TARS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tarsus Pharmaceuticals Inc (TARS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Tarsus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:TARS) - TradingView
TARS Forecast — Price Target — Prediction for 2027 - TradingView
Tarsus (TARS) CEO Azamian sells 10,000 shares via 10b5-1 trading plan - Stock Titan
Tarsus: Not Cheap, But Xdemvy Makes The Valuation Work - Seeking Alpha
Tarsus Pharmaceuticals director sells $183,384 in company stock By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals director sells $183,384 in company stock - Investing.com UK
Tarsus Pharmaceuticals Inc Azioni (TARS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tarsus Pharmaceuticals Inc Azioni (TARS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farrow Jeffrey S | See Remarks |
Jun 16 '26 |
Sale |
60.95 |
14,396 |
877,436 |
56,801 |
| Goodrich Katherine | Director |
Jun 15 '26 |
Sale |
62.08 |
2,954 |
183,384 |
2,233 |
| LINK WILLIAM J PHD | Director |
Jun 15 '26 |
Sale |
62.12 |
12,500 |
776,495 |
106,786 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):